Bio+ech Connec+, is a unique forum for early-stage Canadian biotech companies to connect directly with the business development and investment leaders of multinational pharma/biotech companies.
This virtual forum will include a plenary session led by Lizabeth Leveille, Vice President, Business Development & Licensing, Head, Boston & European Innovation Hubs & Discovery Transactions, and Marwan Akar, President & Managing Director – Merck Canada providing an overview of the company, its R&D priorities including its pipeline and corresponding investment priorities for the period ahead.
Merck representatives will then engage in a Q&A session with the plenary audience. Following the plenary and Q&A, a select group of early-stage companies will be provided an opportunity to connect bilaterally with the Merck representatives.
Plenary and Q&A will run 1:00-2:00 ET. The opening plenary/Q&A session is open to all to participate in at no cost. Save your spot by registering today!
If you would like to participate in a 30-minute one-on-one meeting session with Merck representatives following the plenary, please apply by Wednesday, March 2nd. You will be notified if you have secured a meeting by Thursday, March 10th. (The application process is quick and painless!).
Note: Plenary and Q&A will run approx. 1:00-2:00 PM. Your 30-min meeting will occur at some point after 2:00 PM (ET) in the afternoon of March 16th.
CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that will accelerate the discovery and development of safer and more effective drugs. We bring together world-class pharmaceutical corporations, several Canadian biotech companies, the best scientists from both the public and private sectors, as well as the Canadian and Québec governments. CQDM’s collaborative approach bridges the funding gap needed to drive innovation across the academic and private sectors, especially where early-stage research is concerned. For more information – www.cqdm.org, LinkedIn and Twitter.